Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma

Tumori

Volumn 93, Issue 2, 2007, Pages 138-144

  Tiseo, Marcello ^a   Martelli, Olga ^b   Mancuso, Andrea ^c   Sormani, Maria Pia ^d   Bruzzi, Paolo ^e   Di Salvia, Roberto ^c   De Marinis, Filippo ^c   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

Cisplatin; Hydration; Nephrotoxicity; Outpatient regimen

Indexed keywords

CISPLATIN; CREATININE; DEXAMETHASONE; ETOPOSIDE; FUROSEMIDE; GEMCITABINE; IFOSFAMIDE; MAGNESIUM SULFATE; MITOMYCIN; NAVELBINE; PACLITAXEL; POTASSIUM CHLORIDE; RALTITREXED; SODIUM CHLORIDE; TENIPOSIDE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIURESIS; FEMALE; HUMAN; HYDRATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OUTPATIENT CARE; PLEURA MESOTHELIOMA; SIDE EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34249870118     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300205     Document Type: Article

References (21)

1. Johnson SW, O'Dwyer PJ: Pharmacology of cancer chemotherapy: cisplatin and its analogues. In: Cancer. Principles and practice of oncology, 7th ed, De Vita VT Jr, Hellman S, Rosenberg SA (Eds), pp. 344-358, Lippincott Williams & Wilkins, Philadelphia, 2005.
2. Loehrer P, Einhorn L: Drugs five years later. Cisplatin. Ann Intern Med, 100: 704-713, 1984.
3. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol, 17: 409-422, 1999.
4. Weiss RB: Adverse effects of treatment: miscellaneous toxicities. In: Cancer. Principles and practice of oncology, 7th edn, De Vita VT Jr, Hellman S, Rosenberg SA, (Eds), pp. 2602-2615, Lippincott Williams & Wilkins, Philadelphia, 2005.
5. Finley RS, Fortner CL, Grove WR: Cisplatin nephrotoxicity: A summary of preventative interventions. Drug Intell Clin Pharm, 19: 362-367, 1985.
6. Sobrero A, Guglielmi A, Aschele C, Rosso R: Current strategies to reduce cisplatin toxicity. J Chemother, 2: 3-7, 1990.
7. Cornelison TL, Reed E: Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol, 50: 147-158, 1993.
8. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P: Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol, 35: 1-9, 1994.
9. Hayes D, Cvitkovic E, Golbey R, Scheiner E, Helson L, Krakoff ICH: High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer, 39: 1372-1381, 1977.
10. Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR, Wiernik PH: High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep, 65: 73-78, 1981.
11. Santoso JT, Lucci III JA, Coleman RL, Schafer I, Hannigan EV: Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol, 52: 13-18, 2003.
12. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Platinol. Available at: http://www.fda.gov/cder/foi/label/1993/ 0180571bl.pdf. Accessed January 26, 2006.
13. Arany I, Safirstein RL: Cisplatin Nephrotoxicity. Sem Nephrol, 23: 460-464, 2003.
14. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976.
15. BC Cancer Agency: Cisplatin. Available at: http://www.bc-cancer.bc.ca/ HPI/DrugDatabase/DrugIndexPro/Cisplatin.htm. Accessed October 31, 2006.
16. Marceau D, Poirier M, Masson E, Beaulieu E: High incidence of nephrotoxicity with cisplatin therapy despite adequate hydration: risk factor correlations. Proc Am Soc Clin Oncol, 1999: abstr 840.
17. Dollinger M: Guidelines for hospitalization for chemotherapy. Oncologist, 1: 107-111, 1996.
18. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 346: 92-98, 2002.
19. Cubillo A, Cornide M, Lopez JL, Molina R, Feliu J, Espinosa E, Zamora P, de Castro J, Ordonez A, Gonzalez Baron M: Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol, 24: 192-197, 2001.
20. Pinnaro P, Ruggeri EM, Carlini P, Giovannelli M, Cognetti F: Cumulative or delayed nephrotoxicity after cisplatin (DDP) treatment. Tumori, 72: 197-200, 1986.
21. Mor V, Stalker MZ, Gralla R, Scher HI, Cimma C, Park D, Flaherty AM, Kiss M, Nelson P, Laliberte L: Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial. J Clin Epidemiol, 41: 771-785, 1988.